Intervention

Margetuximab

ClinicalTrials.gov intervention label

Clinical trials6

Recruiting0

Common conditions10

Lead sponsors shown5

Clinical trials

6 shown

Margetuximab Plus Tucatinib and Capecitabine in HER2-positive Metastatic Breast CancerNCT05227131 · 2022-05-15

MARGetuximab Or Trastuzumab (MARGOT)NCT04425018 · 2020-07-13

ACTIVE_NOT_RECRUITING

A Study to Evaluate the Efficacy and Safety of Margetuximab Plus Chemotherapy in the Treatment of Chinese Patients With HER2+ MBCNCT04262804 · 2020-01-13

Margetuximab Plus Chemotherapy vs Trastuzumab Plus Chemotherapy in the Treatment of HER2+ Metastatic Breast CancerNCT02492711 · 2015-08-24

Phase 2 Study of the Monoclonal Antibody MGAH22 (Margetuximab) in Patients With Relapsed or Refractory Advanced Breast CancerNCT01828021 · 2013-03-01

Margetuximab Expanded Access ProgramNCT03133988

APPROVED_FOR_MARKETING

Common conditions

HER2-positive Breast Cancer3 Breast Cancer2 Advanced Breast Cancer1 Breast Cancer Metastatic1 HER-2 Positive Breast Cancer1 HER2-positive Carcinoma1 Metastatic Breast Cancer1 Metastatic Neoplasm1 Stage II Breast Cancer1 Stage III Breast Cancer1

Leading sponsors

MacroGenics2 Dana-Farber Cancer Institute1 MedSIR1 TerSera Therapeutics LLC1 Zai Lab (Shanghai) Co., Ltd.1

Trial status mix

COMPLETED2

ACTIVE_NOT_RECRUITING1

APPROVED_FOR_MARKETING1

UNKNOWN1

WITHDRAWN1

Phase mix

PHASE24

PHASE31

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.